[go: up one dir, main page]

WO2009035055A1 - Insulin-like growth factor-1 (igf-1) production promoter - Google Patents

Insulin-like growth factor-1 (igf-1) production promoter Download PDF

Info

Publication number
WO2009035055A1
WO2009035055A1 PCT/JP2008/066461 JP2008066461W WO2009035055A1 WO 2009035055 A1 WO2009035055 A1 WO 2009035055A1 JP 2008066461 W JP2008066461 W JP 2008066461W WO 2009035055 A1 WO2009035055 A1 WO 2009035055A1
Authority
WO
WIPO (PCT)
Prior art keywords
insulin
growth factor
disorder
production promoter
disclosed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/066461
Other languages
French (fr)
Japanese (ja)
Inventor
Kenji Okajima
Naoaki Harada
Mitsutoshi Watanabe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chemo Sero Therapeutic Research Institute Kaketsuken
Original Assignee
Chemo Sero Therapeutic Research Institute Kaketsuken
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemo Sero Therapeutic Research Institute Kaketsuken filed Critical Chemo Sero Therapeutic Research Institute Kaketsuken
Priority to JP2009532225A priority Critical patent/JPWO2009035055A1/en
Publication of WO2009035055A1 publication Critical patent/WO2009035055A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39516—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from serum, plasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Disclosed is an insulin-like growth factor-1 production promoter. As the main use application of the insulin-like growth factor-1 production promoter, also disclosed is a novel prophylactic/therapeutic agent for various types of organ and tissue disorders (including a renal disorder, a hepatic disorder, a spinal disorder, and a gastric mucosal disorder) which are caused by ischemic reperfusion induced by hemorrhagic shock or a blood circulation disorder. Specifically disclosed is an insulin-like growth factor-1 production promoter comprising, as an active ingredient, a molecular species which contains an Fc region of immunoglobulin-G, and which is derived from a plasma or prepared by employing a genetic recombination technique. As an embodiment of the insulin-like growth factor-1 production promoter, also specifically disclosed is a prophylactic/therapeutic agent for an organ or tissue disorder caused by ischemic reperfusion.
PCT/JP2008/066461 2007-09-14 2008-09-11 Insulin-like growth factor-1 (igf-1) production promoter Ceased WO2009035055A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2009532225A JPWO2009035055A1 (en) 2007-09-14 2008-09-11 Insulin-like growth factor-1 (IGF-1) production promoter

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2007-239142 2007-09-14
JP2007239142 2007-09-14
JP2008-028659 2008-02-08
JP2008028659 2008-02-08

Publications (1)

Publication Number Publication Date
WO2009035055A1 true WO2009035055A1 (en) 2009-03-19

Family

ID=40452062

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/066461 Ceased WO2009035055A1 (en) 2007-09-14 2008-09-11 Insulin-like growth factor-1 (igf-1) production promoter

Country Status (2)

Country Link
JP (1) JPWO2009035055A1 (en)
WO (1) WO2009035055A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010058517A1 (en) * 2008-11-20 2010-05-27 明治乳業株式会社 NERVE CELL STIMULATOR COMPRISING IgG AND/OR Fc FRAGMENT OF IgG
WO2014103410A1 (en) 2012-12-26 2014-07-03 森永乳業株式会社 Igf-1 production promoter

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5598117A (en) * 1979-01-17 1980-07-25 Chemo Sero Therapeut Res Inst Purification of gamma-globulin derivative
JPS63245691A (en) * 1987-03-31 1988-10-12 Teijin Ltd Human immunoglobulin gfc region protein and production thereof
JP2004502412A (en) * 2000-06-08 2004-01-29 ザ　センター　フォー　ブラッド　リサーチ　インコーポレーティッド Methods and compositions for inhibiting immunoglobulin-mediated reperfusion injury

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5598117A (en) * 1979-01-17 1980-07-25 Chemo Sero Therapeut Res Inst Purification of gamma-globulin derivative
JPS63245691A (en) * 1987-03-31 1988-10-12 Teijin Ltd Human immunoglobulin gfc region protein and production thereof
JP2004502412A (en) * 2000-06-08 2004-01-29 ザ　センター　フォー　ブラッド　リサーチ　インコーポレーティッド Methods and compositions for inhibiting immunoglobulin-mediated reperfusion injury

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ANDOH,T.,ET AL.: "Direct action of immunoglobulin G on primary sesory neurons through Fc gamma receptor I", THE FASEB JOURNAL, vol. 18, no. 1, January 2004 (2004-01-01), pages 182 - 184 *
BUERKE,M.,ET AL.: "Cardioprotective effect of insulin-like growth factor I in myocardial ischemia followed by reperfusion", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 92, no. 17, 15 August 1995 (1995-08-15), pages 8031 - 8035 *
GOMEZ-GUERRERO,C.,ET AL.: "Administration if IgG Fc fragments prevents glomerular injury in experimental immune complex nephritis", THE JOURNAL OF IMMUNOLOGY, vol. 164, no. 4, 15 February 2000 (2000-02-15), pages 2092 - 2101 *
HARADA,N.,ET AL.: "Stimulation of sensory neurons by capsaicin increases tissue levels of IGF-I,thereby reducing reperfusion-induced apoptosis in mice", NEUROPHARMACOLOGY, vol. 52, no. 5, April 2007 (2007-04-01), pages 1303 - 1311 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010058517A1 (en) * 2008-11-20 2010-05-27 明治乳業株式会社 NERVE CELL STIMULATOR COMPRISING IgG AND/OR Fc FRAGMENT OF IgG
WO2014103410A1 (en) 2012-12-26 2014-07-03 森永乳業株式会社 Igf-1 production promoter
US9801404B2 (en) 2012-12-26 2017-10-31 Morinaga Milk Industry Co., Ltd. IGF-1 production-promoting agent

Also Published As

Publication number Publication date
JPWO2009035055A1 (en) 2010-12-24

Similar Documents

Publication Publication Date Title
WO2007135527A3 (en) Benzimidazolyl compounds
WO2008057550A3 (en) Stabilization of vaccines by lyophilization
WO2007117465A3 (en) Indazole compounds
WO2009053339A3 (en) Cholesterol derivatives of inhibitors of viral fusion
WO2007084667A3 (en) Fused heterobicyclic kinase inhibitors
WO2007096151A3 (en) Inhibitors of p38-kinase for treatment of pulmonary hypertension
WO2009014650A3 (en) Recombinant vibrio cholerae exotoxins
WO2007084728A3 (en) 2-imino-benzimidazoles
WO2008131149A3 (en) Crystal forms of saxagliptin and processes for preparing same
WO2007107470A3 (en) Pyrazoles as 11-beta-hsd-1
WO2008109142A3 (en) Pirna and uses related thereto
WO2005051325A3 (en) Carvedilol compositions methods of treatment and delivery
WO2008017381A8 (en) Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use
WO2008043544A8 (en) Sulfonamide substituted pyrazoline compounds, their preparation and use as cb1 modulators
MX2009007911A (en) Fused aromatic ptp-1b inhibitors.
WO2007095039A3 (en) Pharmaceutical formulations
WO2008008700A3 (en) Substituted cyclopentane derivatives as therapeutic agents
ZA200607631B (en) Stable injectable diclofenac compositions
WO2007032028A8 (en) Thiazolinones and oxazolinones and their use as ptp1b inhibitors
WO2008067408A3 (en) Method of isolating and propagating stem cells from benign tumors
WO2007133944A3 (en) Topical administration of acyclovir
WO2011056630A3 (en) Small molecule inhibitors of hepatitis c virus
WO2009035055A1 (en) Insulin-like growth factor-1 (igf-1) production promoter
WO2008041134A3 (en) Use of chlorine guanabenz derivatives for treating prion-based diseases
EP2371379A3 (en) New formulation for increasing bioavailability of neurturin

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08831029

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2009532225

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08831029

Country of ref document: EP

Kind code of ref document: A1